Haeng Gyu Lee

LAW FIRM: Jipyong


PRACTICE AREA: Capital markets

Partner Haeng Gyu Lee of Jipyong wins our July lawyer of the month award for his leading role in a record-breaking SK Biopharmaceuticals’ IPO in early July.

SK Biopharmaceuticals, a biotechnology arm of SK Group in South Korea, debuted on the nation’s main bourse Kospi at double its IPO price, setting a new record in domestic IPO history. This is the largest offering in the country in three years.  

Lee and his team, including head of the firm’s bio and healthcare team Tae Hyun Lee, represented the issuer as Korean counsel.

Partner Haeng Gyu Lee leads the capital markets team at Jipyong. His practice covers capital markets, corporate and M&A, private equity and project financing. He has handled several landmark transactions for major Korean corporations such as Korea Investment & Securities, Mirae Asset Daewoo, Samsung Securities and KB Securities, and regularly advises Korean companies on listing on the NASDAQ, TWSE and HKEX.